PROTACs, molecular glues and other degraders

PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha ( ERα )

PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha ( ERα )

PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α ( ERα ) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.

PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α ( ERα ) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.

PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α ( ERα ) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.

PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α ( ERα ) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.

PROTAC IRAK4 degrader-1 is a Cereblon -based PROTAC interleukin-1 receptor-associated kinase 4 ( IRAK4 ) degrader extracted from patent US20190192668A1 Compound I-210, makes &lt:20%, &gt:20-50%, and &gt:50% IRAK4 degradation at 0.01, 0.1, and 1 μM

PROTAC IRAK4 degrader-7 (Compound I-417) is an orally active PROTAC IRAK4 degrader with antitumor activitiesForm:SolidIC50&amp: Target:IRAK4.

PROTAC KRAS G12C degrader-1 is a Cereblon -based KRAS G12C PROTAC degrader. PROTAC KRAS G12C degrader-1 induces CRBN/ KRAS G12C dimerization and degrades GFP- KRAS G12C in reporter cells.Appearance:SolidIn Vitro:PROTAC KRAS G12C degrader-1 (Compound

PROTAC KRAS G12C degrader-1 is a Cereblon -based KRAS G12C PROTAC degrader. PROTAC KRAS G12C degrader-1 induces CRBN/ KRAS G12C dimerization and degrades GFP- KRAS G12C in reporter cells.Appearance:SolidIn Vitro:PROTAC KRAS G12C degrader-1 (Compound

PROTAC KRAS G12C degrader-1 is a Cereblon -based KRAS G12C PROTAC degrader. PROTAC KRAS G12C degrader-1 induces CRBN/ KRAS G12C dimerization and degrades GFP- KRAS G12C in reporter cells.Appearance:SolidIn Vitro:PROTAC KRAS G12C degrader-1 (Compound

PROTAC MDM2 Degrader-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor , linker, and the MDM2 ligand for E3 ubiquitin ligaseForm:SolidIC50&amp: Target:MDM2.